On 9 July, 2015, Meihua Biotechnology Group Co., Ltd. (Meihua Bio) published its H1 2015 performance pre-announcement, according to which the company realized a net profit of USD21.7 million during the period, soaring by around 150% year on year.
The main reason behind the performance increase is that in the first half of 2015, the wholly-owned subsidiary of Meihua Bio, Xinjiang Meihua Amino Acids Co., Ltd., released its capacities gradually. Meanwhile, the company’s output and sales volume of MSG, threonine and lysine rose. In detail, the sales volume of big-package MSG for the domestic market went up by 32.3% year on year; the threonine market recovered, and the unit price and sales volume of the product grew by 15.7% and 11.0% year on year respectively; the sales volume of lysine increased by 46.4% year on year. Increases in sales volume lead to more revenue. At the same time, product prices rose to different degree, resulting in profit growth.
On 9 July, 2015, Meihua Bio announced to transfer the 51% shares that it held in Dalian Hissen Bio-pharm. Co., Ltd. (Dalian Hissen). Through the transfer, Meihua Bio can recycle its cash assets. Specifically, another wholly-owned subsidiary of the company, Lhasa Meihua Bio Investment Holding Co., Ltd., sold the 51% shares that it held in Dalian Hissen to Liaoning Aimei Biological Vaccine Technology Group (Aimei Biological), with the price of USD55.1 million. After this, Dalian Hissen can take full advantage of the R&D, products, technology and market of Aimei Biological. Meihua Bio can also participate in the vaccine platform of Aimei Biological through shareholding and enjoy its benefits from fast development.
Based on the company’s confidence in its future development and reasonable judge of its current share value, the shareholder of Meihua Bio, Hu Jijun, plans to hold more regular stocks of the company in the next six months worth USD58.9 million.
Follow Think Real